MitoSense is pioneering a novel therapeutic approach through its Mitochondria Organelle Transplantation (MOT™) technology, which focuses on addressing mitochondrial dysfunction linked to various neurodegenerative diseases, including ALS, Parkinson's, and Alzheimer's. This innovative cellular biotherapy has shown promising results in early research, demonstrating the potential to alleviate symptoms associated with these disorders. MitoSense holds exclusive licensing for MOT™, which is currently unique in the therapeutic landscape, indicating a significant advancement in the treatment of mitochondrial-related diseases.

The research surrounding MOT™ has revealed its capability to restore mitochondrial function, thereby inhibiting cancer cell growth and potentially reversing chemotherapy resistance. Studies have indicated that mitochondrial health is crucial not only for neurodegenerative diseases but also for conditions like traumatic brain injury and severe COVID-19 cases. MitoSense is actively collaborating with various institutions to further explore the broader applications of MOT™ technology, aiming to enhance the quality of life for millions affected by mitochondrial dysfunction and related diseases.

United States

We are an R&D company with exclusively licensed and patent pending technology to replenish mitochondria to fight disease, including neurodegenerative disorders such as ALS, Alzheimer’s, and Parkinson’s.

MitoSense

Company Details